SS
TXMD icon

SBI Securities’s TherapeuticsMD TXMD Stock Holding History

SBI Securities’s Portfolio TXMD Stock Details TXMD Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$2.79K Buy
1,263
+996
+373% +$2.06K ﹤0.01% 2434
2026
Q1 		$539 Buy
267
+12
+5% +$27 ﹤0.01% 2869
2025
Q4 		$416 Hold
255
– – ﹤0.01% 2941
2025
Q3 		$274 Hold
255
– – ﹤0.01% 3215
2025
Q2 		$296 Hold
255
– – ﹤0.01% 3182
2025
Q1 		$236 Hold
255
– – ﹤0.01% 3164
2024
Q4 		$219 Buy
+255
New +$359 ﹤0.01% 3206

Other funds holding TXMD

AWM
Activest Wealth Management Aventure, Florida $518M AUM 44.34% 1-Year Est. Return
FA
Fedenia Advisers Madison, Wisconsin $421M AUM 96.46% 1-Year Est. Return
FFA
Farther Finance Advisors San Francisco, California $12.8B AUM 26.53% 1-Year Est. Return
IA
IFP Advisors Tampa, Florida $5.54B AUM 27.43% 1-Year Est. Return
PWA
Provenance Wealth Advisors Fort Lauderdale, Florida $1.05B AUM 18.67% 1-Year Est. Return
BWL
Bogart Wealth LLC Mclean, Virginia $2.92B AUM 23.85% 1-Year Est. Return
SWIM
Smallwood Wealth Investment Management Red Bank, New Jersey $229M AUM 23.56% 1-Year Est. Return
EWA
EverSource Wealth Advisors Birmingham, Alabama $2.97B AUM 28.74% 1-Year Est. Return

SBI Securities's TXMD Position: Q2 2026 in Review

SBI Securities increased its TherapeuticsMD (TXMD) stake by 373% in Q2 2026, buying an estimated $2.06K and bringing the position to 1,263 shares worth $2.79K. The position accounts for ﹤0.01% of the portfolio, ranked #2434.

SBI Securities first reported a position in TXMD in Q4 2024 and has held it in 7 quarters since. 9 funds tracked by Wall St. Rank hold TXMD as of Q2 2026.

  • SBI Securities held 1,263 shares of TherapeuticsMD worth $2.79K as of Q2 2026.
  • SBI Securities bought 996 TherapeuticsMD shares in Q2 2026, an estimated $2.06K.
  • TherapeuticsMD made up ﹤0.01% of SBI Securities's portfolio in Q2 2026, its #2434 holding.
  • SBI Securities first reported a position in TherapeuticsMD in Q4 2024 and has held it in 7 quarters since.
  • 9 funds tracked by Wall St. Rank held TherapeuticsMD as of Q2 2026.

Based on SBI Securities's 13F filing for Q2 2026, filed 23 Jul 2026.